Blossom publishes several articles per week that provide commentary on the developing field of psychedelics as medicine. Here we analyse the latest research, provide overviews of research areas, and conduct interviews with leading psychedelic figures.
Psychedelic research in September 2024 covered mescaline dosing, meditation, psilocybin for veterans, harmine dosing, and more
Category: Overviews
Published: 2024-10-08
The psychedelic research from July and August 2024. Covering LSD follow-up, R vs S-MDMA, and false insights after psychedelics.
Category: Overviews
Published: 2024-09-10
Psychedelic research in June 2024 investigated the coupling of psychedelics (and benzos), the role of purging, and ethical guidelines
Category: Overviews
Published: 2024-07-10
Psychedelic research in May 2024 investigates awe in ketamine therapy, role of therapy in PAT, touch guidelines, real world impact of psychedelics, and more.
Category: Overviews
Published: 2024-06-04
April 2024 psychedelic research explores mechanisms, addresses challenges, compares MDMA to amphetamines, reviews 5-MeO-DMT, and investigates novel therapeutic applications for seizures, personality disorders, and cluster headaches.
Category: Overviews
Published: 2024-05-02
Europe explores the future of Psychedelic Medicine in a workshop led by the European Medicines Agency (EMA) - First Day
Category: Research
Published: 2024-04-17
In this recap of the latest psychedelic research from March 2024 we look at meditation, SSRIs, and safety of psychedelics, and 17 more studies.
Category: Overviews
Published: 2024-04-08
What happens if psychedelics become a regular part of therapy? In a way, that is what the majority of research on psychedelics is trying to answer. Studies analysing the safety, to mapping out the effectiveness in various domains, including those featured here in February, help us understand psychedelics as medicines.
Category: Overviews
Published: 2024-03-05
How can microdosing support people who experience ADHD, and does it work better than conventional medications? The first article explores this across two studies. We then venture into the heart of Europe, where psychedelic-assisted psychotherapy has been legally possible for the last decade (again). Finally, I'll focus on the flexible repeated dosing in a trial with psilocybin for depression.
Category: Briefings
Published: 2024-02-21
January saw new psychedelic trials on ibogaine for TBI, DMT, and psilocybin for CCHs, alongside re-analyses on psychedelic brain impacts, therapy dynamics in MDMA treatment, and LSD visuals. Studies also probed SSRI-psychedelic interactions, expectancy roles, and heart effects from microdosing.
Category: Overviews
Published: 2024-02-05
Psychedelic Insights
Blossom provides timely and timeless information on psychedelics as medicine. Our blogs, articles, and interviews help contextualize this quickly developing field of psychedelic research and how this will be implemented.
